PharmaLundensis (PHAL) 주식 개요PharmaLundensis AB operates as a pharmaceutical company. 자세히 보기PHAL 펀더멘털 분석스노우플레이크 점수가치 평가0/6미래 성장0/6과거 실적0/6재무 건전성1/6배당0/6위험 분석의미 있는 시가총액이 없습니다(SEK15M)수익이 USD$1m 미만입니다(SEK0)주식은 유동성이 매우 낮습니다지난 1년 동안 주주가 희석되었습니다.+ 위험 1건 추가모든 위험 점검 보기PHAL Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.Your Fair ValueSEK Current PriceSEK 0.36해당 없음내재 할인율Est. Revenue$PastFuture-12m8k2016201920222025202620282031Revenue SEK 1.0Earnings SEK 0.2AdvancedSet Fair ValueView all narrativesPharmaLundensis AB 경쟁사AptahemSymbol: NGM:APTAMarket cap: SEK 17.1mBiosergenSymbol: OM:BIOSGNMarket cap: SEK 21.1mProstatype GenomicsSymbol: OM:PROGENMarket cap: SEK 27.2mExpreS2ion Biotech HoldingSymbol: OM:EXPRS2Market cap: SEK 5.8m가격 이력 및 성과PharmaLundensis 주가의 최고가, 최저가 및 변동 요약과거 주가현재 주가SEK 0.3652주 최고가SEK 1.5152주 최저가SEK 0.16베타-0.311개월 변동0%3개월 변동1.69%1년 변동-44.62%3년 변동-63.64%5년 변동-90.58%IPO 이후 변동-90.77%최근 뉴스 및 업데이트공시 • Apr 22PharmaLundensis AB to Report Q1, 2026 Results on May 21, 2026PharmaLundensis AB announced that they will report Q1, 2026 results on May 21, 2026공시 • Jan 23PharmaLundensis AB has filed a Follow-on Equity Offering in the amount of SEK 19.997256 million.PharmaLundensis AB has filed a Follow-on Equity Offering in the amount of SEK 19.997256 million. Security Name: Shares Security Type: Common Stock Securities Offered: 39,994,512 Price\Range: SEK 0.5 Transaction Features: Rights Offering공시 • Jan 21PharmaLundensis AB to Report Fiscal Year 2025 Results on Feb 19, 2026PharmaLundensis AB announced that they will report fiscal year 2025 results on Feb 19, 2026공시 • Oct 22PharmaLundensis AB to Report Q3, 2025 Results on Nov 20, 2025PharmaLundensis AB announced that they will report Q3, 2025 results on Nov 20, 2025공시 • Jul 23PharmaLundensis AB to Report Q2, 2025 Results on Aug 21, 2025PharmaLundensis AB announced that they will report Q2, 2025 results on Aug 21, 2025공시 • Jun 10PharmaLundensis AB has filed a Follow-on Equity Offering in the amount of SEK 20.09248 million.PharmaLundensis AB has filed a Follow-on Equity Offering in the amount of SEK 20.09248 million. Security Name: Shares Security Type: Common Stock Securities Offered: 40,184,959 Price\Range: SEK 0.5 Transaction Features: Rights Offering더 많은 업데이트 보기Recent updates공시 • Apr 22PharmaLundensis AB to Report Q1, 2026 Results on May 21, 2026PharmaLundensis AB announced that they will report Q1, 2026 results on May 21, 2026공시 • Jan 23PharmaLundensis AB has filed a Follow-on Equity Offering in the amount of SEK 19.997256 million.PharmaLundensis AB has filed a Follow-on Equity Offering in the amount of SEK 19.997256 million. Security Name: Shares Security Type: Common Stock Securities Offered: 39,994,512 Price\Range: SEK 0.5 Transaction Features: Rights Offering공시 • Jan 21PharmaLundensis AB to Report Fiscal Year 2025 Results on Feb 19, 2026PharmaLundensis AB announced that they will report fiscal year 2025 results on Feb 19, 2026공시 • Oct 22PharmaLundensis AB to Report Q3, 2025 Results on Nov 20, 2025PharmaLundensis AB announced that they will report Q3, 2025 results on Nov 20, 2025공시 • Jul 23PharmaLundensis AB to Report Q2, 2025 Results on Aug 21, 2025PharmaLundensis AB announced that they will report Q2, 2025 results on Aug 21, 2025공시 • Jun 10PharmaLundensis AB has filed a Follow-on Equity Offering in the amount of SEK 20.09248 million.PharmaLundensis AB has filed a Follow-on Equity Offering in the amount of SEK 20.09248 million. Security Name: Shares Security Type: Common Stock Securities Offered: 40,184,959 Price\Range: SEK 0.5 Transaction Features: Rights Offering공시 • Apr 02PharmaLundensis AB to Report Q1, 2025 Results on May 01, 2025PharmaLundensis AB announced that they will report Q1, 2025 results on May 01, 2025공시 • Feb 06PharmaLundensis AB has filed a Follow-on Equity Offering in the amount of SEK 14.439654 million.PharmaLundensis AB has filed a Follow-on Equity Offering in the amount of SEK 14.439654 million. Security Name: Shares Security Type: Common Stock Securities Offered: 14,439,654 Price\Range: SEK 1 Transaction Features: Rights Offering공시 • Jan 22PharmaLundensis AB to Report Fiscal Year 2024 Results on Feb 20, 2025PharmaLundensis AB announced that they will report fiscal year 2024 results on Feb 20, 2025공시 • Oct 23PharmaLundensis AB to Report Nine Months, 2024 Results on Nov 21, 2024PharmaLundensis AB announced that they will report nine months, 2024 results on Nov 21, 2024공시 • Jul 17PharmaLundensis AB to Report Q2, 2024 Results on Aug 15, 2024PharmaLundensis AB announced that they will report Q2, 2024 results on Aug 15, 2024공시 • Apr 17PharmaLundensis AB to Report Q1, 2024 Results on May 16, 2024PharmaLundensis AB announced that they will report Q1, 2024 results on May 16, 2024공시 • Jan 17PharmaLundensis AB to Report Fiscal Year 2023 Results on Feb 15, 2024PharmaLundensis AB announced that they will report fiscal year 2023 results on Feb 15, 2024공시 • Sep 22PharmaLundensis AB to Report Nine Months, 2023 Results on Oct 20, 2023PharmaLundensis AB announced that they will report nine months, 2023 results on Oct 20, 2023Recent Insider Transactions • Sep 07Founder recently bought kr135k worth of stockOn the 5th of September, Staffan Skogvall bought around 225k shares on-market at roughly kr0.60 per share. This transaction amounted to 1.1% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. Staffan has been a buyer over the last 12 months, purchasing a net total of kr471k worth in shares.공시 • Jul 21PharmaLundensis AB to Report Q2, 2023 Results on Aug 17, 2023PharmaLundensis AB announced that they will report Q2, 2023 results on Aug 17, 2023Recent Insider Transactions • Jul 04Founder recently bought kr85k worth of stockOn the 30th of June, Staffan Skogvall bought around 274k shares on-market at roughly kr0.31 per share. This transaction amounted to 1.3% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. Staffan has been a buyer over the last 12 months, purchasing a net total of kr330k worth in shares.New Risk • Jun 17New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 22% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-kr2.3m free cash flow). Share price has been highly volatile over the past 3 months (19% average weekly change). Revenue is less than US$1m. Market cap is less than US$10m (kr19.5m market cap, or US$1.83m). Minor Risk Shareholders have been diluted in the past year (22% increase in shares outstanding).Recent Insider Transactions • Mar 16Founder recently bought kr96k worth of stockOn the 13th of March, Staffan Skogvall bought around 188k shares on-market at roughly kr0.51 per share. This transaction amounted to less than 1% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. Staffan has been a buyer over the last 12 months, purchasing a net total of kr283k worth in shares.공시 • Jan 18PharmaLundensis AB to Report Fiscal Year 2022 Results on Feb 16, 2023PharmaLundensis AB announced that they will report fiscal year 2022 results on Feb 16, 2023Board Change • Nov 16No independent directorsThere are 4 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: 4 new directors. No experienced directors. 1 highly experienced director. No independent directors (5 non-independent directors). Founder, CEO & Director Staffan Skogvall is the most experienced director on the board, commencing their role in 2006. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Lack of experienced directors.공시 • Oct 19PharmaLundensis AB to Report Q3, 2022 Results on Nov 17, 2022PharmaLundensis AB announced that they will report Q3, 2022 results on Nov 17, 2022Board Change • Apr 27No independent directorsThere are 4 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: 4 new directors. No experienced directors. 1 highly experienced director. No independent directors (5 non-independent directors). Founder, CEO & Director Staffan Skogvall is the most experienced director on the board, commencing their role in 2006. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Lack of experienced directors.공시 • Apr 20PharmaLundensis AB to Report Q1, 2022 Results on May 19, 2022PharmaLundensis AB announced that they will report Q1, 2022 results on May 19, 2022Is New 90 Day High Low • Jan 29New 90-day low: kr0.86The company is down 17% from its price of kr1.04 on 29 October 2020. The Swedish market is up 17% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is up 4.0% over the same period.Is New 90 Day High Low • Dec 01New 90-day low: kr0.94The company is down 19% from its price of kr1.16 on 01 September 2020. The Swedish market is up 9.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is down 5.0% over the same period.Is New 90 Day High Low • Oct 24New 90-day low: kr1.01The company is down 8.0% from its price of kr1.10 on 23 July 2020. The Swedish market is up 7.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is down 3.0% over the same period.Is New 90 Day High Low • Sep 23New 90-day low: kr1.02The company is down 15% from its price of kr1.20 on 25 June 2020. The Swedish market is up 12% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is up 16% over the same period.공시 • Jul 26PharmaLundensis AB to Report Q2, 2020 Results on Aug 20, 2020PharmaLundensis AB announced that they will report Q2, 2020 results on Aug 20, 2020주주 수익률PHALSE BiotechsSE 시장7D0%-0.04%-0.2%1Y-44.6%29.4%13.0%전체 주주 수익률 보기수익률 대 산업: PHAL은 지난 1년 동안 29.4%의 수익을 기록한 Swedish Biotechs 산업보다 저조한 성과를 냈습니다.수익률 대 시장: PHAL은 지난 1년 동안 13%를 기록한 Swedish 시장보다 저조한 성과를 냈습니다.주가 변동성Is PHAL's price volatile compared to industry and market?PHAL volatilityPHAL Average Weekly Movementn/aBiotechs Industry Average Movement8.9%Market Average Movement6.3%10% most volatile stocks in SE Market13.5%10% least volatile stocks in SE Market3.7%안정적인 주가: PHAL는 지난 3개월 동안 Swedish 시장에 비해 주가 변동성이 크지 않았습니다.시간에 따른 변동성: Insufficient data to determine PHAL의 변동성 변화를 판단할 수 없습니다.회사 소개설립직원 수CEO웹사이트20061Staffan Skogvallwww.pharmalundensis.se더 보기PharmaLundensis AB 기초 지표 요약PharmaLundensis의 순이익과 매출은 시가총액과 어떻게 비교됩니까?PHAL 기초 통계시가총액SEK 15.28m순이익 (TTM)-SEK 4.40m매출 (TTM)n/a0.0x주가매출비율(P/S)-3.5x주가수익비율(P/E)PHAL는 고평가되어 있습니까?공정 가치 및 평가 분석 보기순이익 및 매출최근 실적 보고서(TTM)의 주요 수익성 지표PHAL 손익계산서 (TTM)매출SEK 0매출원가SEK 0총이익SEK 0기타 비용SEK 4.40m순이익-SEK 4.40m최근 보고된 실적Dec 31, 2023다음 실적 발표일May 16, 2024주당순이익(EPS)-0.10총이익률0.00%순이익률0.00%부채/자본 비율163.1%PHAL의 장기 실적은 어땠습니까?과거 실적 및 비교 보기View Valuation기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2024/04/29 15:49종가2024/01/31 00:00수익2023/12/31연간 수익2023/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스PharmaLundensis AB는 0명의 분석가가 다루고 있습니다. 이 중 0명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
공시 • Apr 22PharmaLundensis AB to Report Q1, 2026 Results on May 21, 2026PharmaLundensis AB announced that they will report Q1, 2026 results on May 21, 2026
공시 • Jan 23PharmaLundensis AB has filed a Follow-on Equity Offering in the amount of SEK 19.997256 million.PharmaLundensis AB has filed a Follow-on Equity Offering in the amount of SEK 19.997256 million. Security Name: Shares Security Type: Common Stock Securities Offered: 39,994,512 Price\Range: SEK 0.5 Transaction Features: Rights Offering
공시 • Jan 21PharmaLundensis AB to Report Fiscal Year 2025 Results on Feb 19, 2026PharmaLundensis AB announced that they will report fiscal year 2025 results on Feb 19, 2026
공시 • Oct 22PharmaLundensis AB to Report Q3, 2025 Results on Nov 20, 2025PharmaLundensis AB announced that they will report Q3, 2025 results on Nov 20, 2025
공시 • Jul 23PharmaLundensis AB to Report Q2, 2025 Results on Aug 21, 2025PharmaLundensis AB announced that they will report Q2, 2025 results on Aug 21, 2025
공시 • Jun 10PharmaLundensis AB has filed a Follow-on Equity Offering in the amount of SEK 20.09248 million.PharmaLundensis AB has filed a Follow-on Equity Offering in the amount of SEK 20.09248 million. Security Name: Shares Security Type: Common Stock Securities Offered: 40,184,959 Price\Range: SEK 0.5 Transaction Features: Rights Offering
공시 • Apr 22PharmaLundensis AB to Report Q1, 2026 Results on May 21, 2026PharmaLundensis AB announced that they will report Q1, 2026 results on May 21, 2026
공시 • Jan 23PharmaLundensis AB has filed a Follow-on Equity Offering in the amount of SEK 19.997256 million.PharmaLundensis AB has filed a Follow-on Equity Offering in the amount of SEK 19.997256 million. Security Name: Shares Security Type: Common Stock Securities Offered: 39,994,512 Price\Range: SEK 0.5 Transaction Features: Rights Offering
공시 • Jan 21PharmaLundensis AB to Report Fiscal Year 2025 Results on Feb 19, 2026PharmaLundensis AB announced that they will report fiscal year 2025 results on Feb 19, 2026
공시 • Oct 22PharmaLundensis AB to Report Q3, 2025 Results on Nov 20, 2025PharmaLundensis AB announced that they will report Q3, 2025 results on Nov 20, 2025
공시 • Jul 23PharmaLundensis AB to Report Q2, 2025 Results on Aug 21, 2025PharmaLundensis AB announced that they will report Q2, 2025 results on Aug 21, 2025
공시 • Jun 10PharmaLundensis AB has filed a Follow-on Equity Offering in the amount of SEK 20.09248 million.PharmaLundensis AB has filed a Follow-on Equity Offering in the amount of SEK 20.09248 million. Security Name: Shares Security Type: Common Stock Securities Offered: 40,184,959 Price\Range: SEK 0.5 Transaction Features: Rights Offering
공시 • Apr 02PharmaLundensis AB to Report Q1, 2025 Results on May 01, 2025PharmaLundensis AB announced that they will report Q1, 2025 results on May 01, 2025
공시 • Feb 06PharmaLundensis AB has filed a Follow-on Equity Offering in the amount of SEK 14.439654 million.PharmaLundensis AB has filed a Follow-on Equity Offering in the amount of SEK 14.439654 million. Security Name: Shares Security Type: Common Stock Securities Offered: 14,439,654 Price\Range: SEK 1 Transaction Features: Rights Offering
공시 • Jan 22PharmaLundensis AB to Report Fiscal Year 2024 Results on Feb 20, 2025PharmaLundensis AB announced that they will report fiscal year 2024 results on Feb 20, 2025
공시 • Oct 23PharmaLundensis AB to Report Nine Months, 2024 Results on Nov 21, 2024PharmaLundensis AB announced that they will report nine months, 2024 results on Nov 21, 2024
공시 • Jul 17PharmaLundensis AB to Report Q2, 2024 Results on Aug 15, 2024PharmaLundensis AB announced that they will report Q2, 2024 results on Aug 15, 2024
공시 • Apr 17PharmaLundensis AB to Report Q1, 2024 Results on May 16, 2024PharmaLundensis AB announced that they will report Q1, 2024 results on May 16, 2024
공시 • Jan 17PharmaLundensis AB to Report Fiscal Year 2023 Results on Feb 15, 2024PharmaLundensis AB announced that they will report fiscal year 2023 results on Feb 15, 2024
공시 • Sep 22PharmaLundensis AB to Report Nine Months, 2023 Results on Oct 20, 2023PharmaLundensis AB announced that they will report nine months, 2023 results on Oct 20, 2023
Recent Insider Transactions • Sep 07Founder recently bought kr135k worth of stockOn the 5th of September, Staffan Skogvall bought around 225k shares on-market at roughly kr0.60 per share. This transaction amounted to 1.1% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. Staffan has been a buyer over the last 12 months, purchasing a net total of kr471k worth in shares.
공시 • Jul 21PharmaLundensis AB to Report Q2, 2023 Results on Aug 17, 2023PharmaLundensis AB announced that they will report Q2, 2023 results on Aug 17, 2023
Recent Insider Transactions • Jul 04Founder recently bought kr85k worth of stockOn the 30th of June, Staffan Skogvall bought around 274k shares on-market at roughly kr0.31 per share. This transaction amounted to 1.3% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. Staffan has been a buyer over the last 12 months, purchasing a net total of kr330k worth in shares.
New Risk • Jun 17New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 22% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-kr2.3m free cash flow). Share price has been highly volatile over the past 3 months (19% average weekly change). Revenue is less than US$1m. Market cap is less than US$10m (kr19.5m market cap, or US$1.83m). Minor Risk Shareholders have been diluted in the past year (22% increase in shares outstanding).
Recent Insider Transactions • Mar 16Founder recently bought kr96k worth of stockOn the 13th of March, Staffan Skogvall bought around 188k shares on-market at roughly kr0.51 per share. This transaction amounted to less than 1% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. Staffan has been a buyer over the last 12 months, purchasing a net total of kr283k worth in shares.
공시 • Jan 18PharmaLundensis AB to Report Fiscal Year 2022 Results on Feb 16, 2023PharmaLundensis AB announced that they will report fiscal year 2022 results on Feb 16, 2023
Board Change • Nov 16No independent directorsThere are 4 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: 4 new directors. No experienced directors. 1 highly experienced director. No independent directors (5 non-independent directors). Founder, CEO & Director Staffan Skogvall is the most experienced director on the board, commencing their role in 2006. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Lack of experienced directors.
공시 • Oct 19PharmaLundensis AB to Report Q3, 2022 Results on Nov 17, 2022PharmaLundensis AB announced that they will report Q3, 2022 results on Nov 17, 2022
Board Change • Apr 27No independent directorsThere are 4 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: 4 new directors. No experienced directors. 1 highly experienced director. No independent directors (5 non-independent directors). Founder, CEO & Director Staffan Skogvall is the most experienced director on the board, commencing their role in 2006. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Lack of experienced directors.
공시 • Apr 20PharmaLundensis AB to Report Q1, 2022 Results on May 19, 2022PharmaLundensis AB announced that they will report Q1, 2022 results on May 19, 2022
Is New 90 Day High Low • Jan 29New 90-day low: kr0.86The company is down 17% from its price of kr1.04 on 29 October 2020. The Swedish market is up 17% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is up 4.0% over the same period.
Is New 90 Day High Low • Dec 01New 90-day low: kr0.94The company is down 19% from its price of kr1.16 on 01 September 2020. The Swedish market is up 9.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is down 5.0% over the same period.
Is New 90 Day High Low • Oct 24New 90-day low: kr1.01The company is down 8.0% from its price of kr1.10 on 23 July 2020. The Swedish market is up 7.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is down 3.0% over the same period.
Is New 90 Day High Low • Sep 23New 90-day low: kr1.02The company is down 15% from its price of kr1.20 on 25 June 2020. The Swedish market is up 12% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is up 16% over the same period.
공시 • Jul 26PharmaLundensis AB to Report Q2, 2020 Results on Aug 20, 2020PharmaLundensis AB announced that they will report Q2, 2020 results on Aug 20, 2020
